Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.81 |
| ▸ | BRAF | P15056 | 3/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | FLT1 | P17948 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520904 | 0.93 | KDR (0.90) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2515513 | 0.92 | KDR (0.87) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2518700 | 0.92 | KDR (0.87) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL13499007 | 0.91 | KDR (0.86) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2517813 | 0.90 | KDR (0.84) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL12205895 | 0.90 | KDR (1.00) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL13499008 | 0.89 | KDR (0.82) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2514123 | 0.88 | KDR (0.80) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL3487053 | 0.87 | KDR (0.79) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2517103 | 0.87 | KDR (0.83) | KDRBRAFPDGFRBKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | KDR 1805/4885BRAF 801/4885PDGFRB 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.